FY2026 Earnings Forecast for Ardelyx Issued By HC Wainwright

Ardelyx, Inc. (NASDAQ:ARDX) – Equities researchers at HC Wainwright upped their FY2026 earnings estimates for Ardelyx in a report issued on Friday, February 20th. HC Wainwright analyst M. Caufield now forecasts that the biopharmaceutical company will post earnings per share of $0.18 for the year, up from their prior forecast of $0.12. HC Wainwright currently has a “Buy” rating and a $18.00 price target on the stock. The consensus estimate for Ardelyx’s current full-year earnings is ($0.18) per share.

Ardelyx (NASDAQ:ARDX) last released its earnings results on Thursday, February 19th. The biopharmaceutical company reported ($0.01) earnings per share for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.03). The firm had revenue of $125.22 million during the quarter, compared to analyst estimates of $118.04 million. Ardelyx had a negative return on equity of 40.63% and a negative net margin of 15.12%.The business’s revenue for the quarter was up 7.8% on a year-over-year basis. During the same quarter last year, the company earned $0.02 earnings per share.

Other equities research analysts have also recently issued reports about the stock. Wedbush reiterated an “outperform” rating and issued a $19.00 price target on shares of Ardelyx in a research report on Monday. Raymond James Financial reaffirmed a “strong-buy” rating and issued a $19.00 price objective on shares of Ardelyx in a research note on Thursday, January 8th. Jefferies Financial Group reissued a “buy” rating and set a $15.00 target price on shares of Ardelyx in a research note on Tuesday, January 27th. BTIG Research restated a “buy” rating and set a $17.00 target price on shares of Ardelyx in a report on Friday. Finally, Citigroup lifted their price target on shares of Ardelyx from $11.00 to $14.00 and gave the stock a “buy” rating in a research report on Friday, January 9th. Two investment analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, Ardelyx presently has a consensus rating of “Buy” and a consensus target price of $15.09.

Ardelyx Trading Up 0.3%

Shares of Ardelyx stock opened at $5.75 on Monday. The business has a fifty day simple moving average of $6.76 and a 200-day simple moving average of $6.13. Ardelyx has a fifty-two week low of $3.21 and a fifty-two week high of $8.40. The firm has a market cap of $1.41 billion, a price-to-earnings ratio of -23.00 and a beta of 0.57. The company has a quick ratio of 4.11, a current ratio of 4.31 and a debt-to-equity ratio of 1.21.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Mercer Global Advisors Inc. ADV lifted its holdings in shares of Ardelyx by 4.7% during the fourth quarter. Mercer Global Advisors Inc. ADV now owns 38,512 shares of the biopharmaceutical company’s stock valued at $225,000 after acquiring an additional 1,722 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Ardelyx by 26.7% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 11,807 shares of the biopharmaceutical company’s stock valued at $69,000 after purchasing an additional 2,491 shares during the last quarter. Universal Beteiligungs und Servicegesellschaft mbH increased its stake in shares of Ardelyx by 0.7% in the 4th quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 347,609 shares of the biopharmaceutical company’s stock valued at $2,027,000 after buying an additional 2,532 shares during the period. Merit Financial Group LLC increased its position in Ardelyx by 12.0% in the third quarter. Merit Financial Group LLC now owns 23,680 shares of the biopharmaceutical company’s stock worth $130,000 after purchasing an additional 2,537 shares during the period. Finally, Brighton Jones LLC lifted its position in Ardelyx by 25.1% during the 3rd quarter. Brighton Jones LLC now owns 12,701 shares of the biopharmaceutical company’s stock valued at $70,000 after purchasing an additional 2,550 shares during the period. Hedge funds and other institutional investors own 58.92% of the company’s stock.

Insiders Place Their Bets

In other Ardelyx news, insider Eric Duane Foster sold 10,439 shares of the business’s stock in a transaction on Friday, February 20th. The shares were sold at an average price of $5.85, for a total transaction of $61,068.15. Following the sale, the insider directly owned 425,970 shares of the company’s stock, valued at $2,491,924.50. The trade was a 2.39% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Michael Raab sold 45,982 shares of the stock in a transaction on Friday, February 20th. The shares were sold at an average price of $5.85, for a total value of $268,994.70. Following the completion of the sale, the chief executive officer owned 1,856,986 shares of the company’s stock, valued at $10,863,368.10. The trade was a 2.42% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 136,938 shares of company stock valued at $857,587 over the last 90 days. 4.80% of the stock is owned by corporate insiders.

Ardelyx News Roundup

Here are the key news stories impacting Ardelyx this week:

• Positive Sentiment: Director David M. Mott purchased 333,333 shares (~$1.95M) at about $5.84, increasing his stake by ~11.2% — a strong insider vote of confidence that can support the stock. SEC Filing: Director Purchase
• Positive Sentiment: Wedbush reaffirmed an “outperform” rating and set a $19 price target (large upside vs. current levels), which can attract buyers and boost sentiment. Wedbush Note via Benzinga
• Positive Sentiment: Other firms reiterated bullish views (BTIG buy rating; HC Wainwright optimistic on FY2026 earnings), reinforcing analyst support that can sustain buying interest. BTIG Reiteration HC Wainwright Note
• Neutral Sentiment: Quarterly revenue beat estimates ($125.2M vs. $118.0M) and year-over-year revenue growth of ~7.8% — a constructive fundamental datapoint, though offset by an EPS miss. (Earnings release was on Feb 19.)
• Negative Sentiment: Earnings EPS missed expectations (reported a loss vs. small expected profit), which triggered a sell-off (shares were reported down ~10.4% after the earnings release). EPS misses typically pressure sentiment and can lead to continued volatility. Earnings Reaction
• Negative Sentiment: Multiple insiders — including the CEO, CFO and several executives — sold shares on Feb 20 (notably the CEO sold ~45,982 shares). Clustered insider selling can be read as profit-taking or reduced insider conviction and may weigh on sentiment. (These sales occurred near $5.85.) SEC Filing: CEO Sale

About Ardelyx

Ardelyx, Inc (NASDAQ: ARDX) is a clinical‐stage biopharmaceutical company focused on discovering, developing and commercializing targeted small molecule drugs for cardio‐renal and gastrointestinal diseases. The company’s lead marketed product, tenapanor (sold under the brand name XPHOZAH in the United States), is approved for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis. Ardelyx’s proprietary approach targets epithelial transporters in the gastrointestinal tract, offering localized activity with limited systemic exposure.

Beyond tenapanor, Ardelyx’s development pipeline includes treatments designed to address other complications in kidney disease and related metabolic disorders.